Synergy between 메이저카지노 linker platform ‘AbClick’ and WuXi XDC CMC Platform

An 메이저카지노 researcher conducting research. (Source: 메이저카지노)
An 메이저카지노 researcher conducting research. (Source: 메이저카지노)

[by Ji, Yong Jun] AbTis, a company specializing in antibody drug conjugate (ADC) 메이저카지노, announced on March 12 that it has signed a memorandum of understanding (MOU) with WuXi XDC, a global contract research, 메이저카지노, and manufacturing organization (CRDMO) for ADCs, to collaborate on the 메이저카지노 of next-generation ADC therapeutics.

The MOU aims to integrate AbTis’ linker platform technology, ‘AbClick,’ with WuXi XDC’s ‘CMC (chemistry, manufacturing, quality control) 메이저카지노 platform’ to expedite the 메이저카지노 of next-generation ADCs and improve efficiency. Through this collaboration, WuXi XDC will introduce AbTis’ AbClick platform and selective drug conjugate technology while offering AbTis the opportunity to expand its global footprint by leveraging WuXi XDC’s extensive global network.

The two companies plan to strengthen their CMC platform capabilities and introduce innovative, cutting-edge solutions in the ADC field. This includes accelerating the 메이저카지노 of next-generation ADCs from preclinical candidate selection for global customers and reducing the CMC 메이저카지노 timeline.

“This collaboration with AbTis is a strategic partnership that will drive innovation and deliver meaningful value to our customers,” expressed Jimmy Li, CEO of Wuxi XDC. “We believe that the integration of our technologies will offer tailored ADC 메이저카지노 solutions to meet our customers’ needs.”

“The synergy between our company’s ADC technology and WuXi XDC’s vast global network and ADC manufacturing capabilities will be substantial,” stated Han Tae-dong, CEO of AbTis. “We will take the lead in driving and supporting the 메이저카지노 of groundbreaking ADC therapeutics, creating opportunities to benefit patients worldwide,” he added.

On the other hand, AbTis is a company specializing in ADC 메이저카지노, equipped with ‘AbClick,’ a third-generation linker technology that facilitates selective binding to target sites. WuXi XDC is a global firm listed on the Hong Kong Exchanges and Clearing that provides comprehensive services throughout the entire ADC research, 메이저카지노, and manufacturing (CRDMO) process.

저작권자 © 더바이오 무단전재 및 재배포 금지